Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020208 | 0.82 | HTT (0.46) | POLBMEN1KMT2AHPGD | |
| SCHEMBL31614861 | 0.82 | HTT (0.46) | POLBMEN1KMT2AHPGD | |
| SCHEMBL2023567 | 0.82 | L3MBTL1 (0.42) | SMN1; SMN2EPHX2 | |
| SCHEMBL2021382 | 0.78 | HTT (0.46) | POLBTHRATHRBMEN1LMNA | |
| SCHEMBL16312388 | 0.77 | KMT2A (0.47) | POLBMEN1LMNAKMT2AENPP2 | |
| SCHEMBL2016622 | 0.73 | GBA1 (0.45) | THRATHRBLMNAEPHX1 | |
| SCHEMBL2017266 | 0.73 | GBA1 (0.47) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2016511 | 0.73 | NPC1 (0.42) | MEN1LMNAKMT2AS1PR1S1PR3 | |
| SCHEMBL2017490 | 0.72 | MGLL (0.44) | HPGD | |
| SCHEMBL21597967 | 0.68 | ENPP2 (0.69) | POLBTHRATHRBLMNAENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | claimed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | claimed |
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | disclosed |
| US-9334302-B2 | Method for removing FMOC group | AJINOMOTO CO., INC. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9206230-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140371424-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8859732-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | AJINOMOTO CO., INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | SPHK1 3003/4885POLB 172/4885THRA 2680/4885 |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | SPHK1 4095/4885POLB 101/4885THRA 2016/4885 |
| US-20110160433-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | SPHK1 2695/4885POLB 3366/4885THRA 3778/4885 |
| US-20140371424-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | SPHK1 2695/4885POLB 3366/4885THRA 3778/4885 |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | ESD, HM13, FURIN | SPHK1 963/4885POLB 3678/4885THRA 3109/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | SPHK1 4095/4885POLB 101/4885THRA 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.